China Biologic Products, Inc. (CBPO) Given $131.67 Consensus Target Price by Brokerages

China Biologic Products, Inc. (NASDAQ:CBPO) has earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus price target of $131.67 for the company and are forecasting that the company will post $1.30 EPS for the current quarter, according to Zacks. Zacks has also given China Biologic Products an industry rank of 159 out of 265 based on the ratings given to related companies.

A number of equities research analysts have recently weighed in on the company. Jefferies Group LLC restated a “buy” rating on shares of China Biologic Products in a research report on Friday, August 4th. BidaskClub downgraded China Biologic Products from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research downgraded China Biologic Products from a “hold” rating to a “sell” rating in a research report on Monday, August 7th.

A number of large investors have recently bought and sold shares of CBPO. Oppenheimer Asset Management Inc. acquired a new position in China Biologic Products in the first quarter valued at about $156,000. Nomura Holdings Inc. acquired a new position in China Biologic Products in the first quarter valued at about $463,000. Jennison Associates LLC boosted its position in shares of China Biologic Products by 0.8% during the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock worth $653,000 after buying an additional 44 shares during the period. AHL Partners LLP acquired a new position in shares of China Biologic Products during the second quarter worth about $842,000. Finally, First Trust Advisors LP boosted its position in shares of China Biologic Products by 35.9% during the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock worth $1,158,000 after buying an additional 3,053 shares during the period. 72.82% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.com-unik.info/2017/10/12/china-biologic-products-inc-cbpo-given-131-67-consensus-target-price-by-brokerages.html.

Shares of China Biologic Products (NASDAQ:CBPO) traded down 14.99% on Thursday, hitting $82.59. The stock had a trading volume of 1,488,845 shares. China Biologic Products has a 52 week low of $82.29 and a 52 week high of $125.99. The firm has a 50 day moving average price of $93.45 and a 200-day moving average price of $103.23. The company has a market cap of $2.25 billion, a price-to-earnings ratio of 21.50 and a beta of 1.75.

China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The firm had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. During the same quarter in the previous year, the company posted $1.26 EPS. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. Analysts anticipate that China Biologic Products will post $4.95 EPS for the current year.

About China Biologic Products

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about China Biologic Products Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for China Biologic Products Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit